ArticleMolecular biology reports2025
Epigenetic modulation of ALKBH5, FTO and YTHDF2 genes in crimean-congo haemorrhagic fever patients depending on RNA methylation.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCrimean-Congo Hemorrhagic Fever (CCHF) is a tick-borne disease caused by a virus belonging to the Orthonairovirus genus. Mononuclear phagocytic cells, hepatocytes and endothelial cells are known to be the primary targets of the CCHF virus during the infection. Epitranscriptomes refers to all chemical modifications of RNA within a cell. The most common among these-and the focus of this study- is N6-methyladenosine (m6A) methylation. METHODS AND
resultsIn this study, for the first time, we investigated the expression profiles of ALKBH5, FTO and YTHDF2 genes using quantitative real-time polymerase chain reaction (qPCR) in CCHF patients. The case group consisted of individuals diognosed with CCHF, while the control group comprised healthy individuals with no active infections. The patient group was further classified into mild and severe cases based on clinical presentation. The expression of the ALKBH5 and YTHDF2 genes was statistically significantly upregulated in fatals (p < 0.001). In addition, ALKBH5 genes were differentially expressed in fatals compared to nonfatal case (p = 0.005). Furthermore, we found that FTO gene was significantly upregulated in severe CCHF patients (p = 0.03). We also compared gene expression levels in patients grouped by clinical parameters that above or within normal limits. FTO expression was found to be significantly decreased in patient with elevated ALT and AST levels (p = 0.043 and p = 0.048, respectively).
conclusionWe suggest that upregulated expression of these genes may be associated with CCHF prognosis. These genes may also serve as potential molecular biomarker for diseaase progression.
Indexed as
Identifiers
40815491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.